Amanta Healthcare Limited is coming up with its Initial Public Offering (IPO) which has drawn considerable attention in the healthcare and pharma segment. This Ahmedabad-based pharmaceutical company is known for its sterile liquid formulations, IV fluids, and medical devices. The IPO is a fresh issue worth ₹126 crore and aims to fund expansion projects, particularly new manufacturing lines at Hariyala, Gujarat. In this Amanta Healthcare IPO Review, let us deep dive into the company’s business model, competitive strengths, issue details, financials, valuations, grey market premium (GMP), reasons to invest, risk factors, and finally conclude whether investors should subscribe or avoid this IPO.
About Amanta Healthcare Ltd.
Incorporated in 1994, Amanta Healthcare is engaged in the manufacturing and marketing of sterile liquid pharmaceutical products. The company’s core portfolio includes IV fluids, diluents, ophthalmic solutions, irrigation solutions, eye lubricants, and respiratory care products. It uses Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies in its manufacturing.
The company operates across three business units:
- National sales through 320+ distributors in India.
- International sales with presence in 19 registered countries.
- Product partnering with Indian and foreign pharmaceutical players.
Amanta Healthcare has a workforce of over 1,700 employees and sells products in Africa, Latin America, the UK, and several other regions. In FY25, it exported branded products to 21 countries.
Competitive Strengths
- Diversified portfolio – Fluid therapy, ophthalmic, respiratory care and medical devices.
- Strong domestic and international network – Products registered in multiple geographies.
- Large-scale manufacturing – Advanced facilities with strong compliance to global standards.
- Experienced management – Led by promoters with decades of pharma expertise.
- Improving profitability – Significant turnaround in FY25 with PAT growth of 189%.
Amanta Healthcare IPO Issue Details
- IPO Opening Date: September 1, 2025
- IPO Closing Date: September 3, 2025
- Issue Type: Book Building IPO
- Face Value: ₹10 per share
- Price Band: ₹120 – ₹126 per share
- Lot Size: 119 shares
- IPO Size: 1 crore shares aggregating up to ₹126 crore
- Listing: BSE, NSE
- Lead Manager: Beeline Capital Advisors Pvt. Ltd.
- Registrar: MUFG Intime India Pvt. Ltd.
Reservation
- QIB: Up to 50%
- Retail: At least 35%
- NII: At least 15%
IPO Timeline
- Allotment: September 4, 2025
- Refunds & Credit to Demat: September 8, 2025
- Listing Date: September 9, 2025
Company Financials
| Particulars (₹ Cr) | FY23 | FY24 | FY25 |
|---|---|---|---|
| Total Income | 262.7 | 281.6 | 276.1 |
| EBITDA | 56.3 | 58.8 | 61.1 |
| PAT | -2.1 | 3.6 | 10.5 |
| Net Worth | 62.9 | 66.3 | 96.4 |
| Total Borrowings | 215.7 | 205.2 | 195.0 |
Key Ratios (FY25):
- ROE: 12.4%
- ROCE: 13.7%
- Debt/Equity: 2.02x
- PAT Margin: 3.86%
- EBITDA Margin: 22.1%
Objects of the IPO
- Funding capex for civil construction and equipment purchase for new SteriPort manufacturing line – ₹70 Cr.
- Setting up new SVP manufacturing line – ₹30.13 Cr.
- General corporate purposes.
Valuation and P/E Comparison
- EPS (FY25 Post IPO): ₹2.70
- P/E Ratio (Post IPO at ₹126): 46.6x
Peer Comparison (Pharma Sector)
- Sun Pharma: ~72x (Highest)
- Aurobindo Pharma: ~20x (Lowest)
- Industry Average: ~35x
At 46.6x P/E, Amanta Healthcare is valued above industry average but below top-tier players like Sun Pharma.
Reasons to Invest in Amanta Healthcare IPO
- Diversified product portfolio with a strong presence in IV fluids and medical devices.
- Export-driven growth with presence in 19+ regulated markets.
- Improving profitability – Turned around from losses in FY23 to strong profits in FY25.
- Capex-driven expansion – New manufacturing lines expected to boost capacity and revenue.
- Strong demand outlook – Rising healthcare spending globally supports IV fluid and medical device demand.
Risk Factors in Amanta Healthcare IPO
- High debt levels (Debt/Equity at 2.0x) could stress cash flows.
- Thin margins – PAT margin of only 3.86% in FY25.
- Intense competition in pharma and generics industry.
- Regulatory risks – Dependence on multiple foreign approvals.
- Valuation premium – At 46.6x P/E, IPO is priced higher than industry average.
Grey Market Premium (GMP)
As of now, Amanta Healthcare IPO GMP is ₹18 – ₹20 per share, indicating a listing gain potential of around 15-16% over the upper price band.
How to Apply for Amanta Healthcare IPO
Investors can apply for Amanta Healthcare IPO via:
- ASBA (Net Banking): Through your bank’s IPO section.
- UPI-based IPO Apps: Zerodha, Upstox, Groww, Angel One, etc.
Conclusion – Should you Invest in Amanta Healthcare IPO?
Amanta Healthcare IPO comes with a strong business model, improving profitability, and expansion plans that can drive future growth. However, high debt, regulatory risks, and premium valuations are key concerns.
- Short-term investors: May consider investing for listing gains given healthy GMP trends.
- Long-term investors: Should weigh risks of high debt and low margins before subscribing.
Recommendation: Investors with high-risk appetite can SUBSCRIBE for listing gains, while conservative investors may AVOID or wait for better entry post listing.
FAQs on Amanta Healthcare IPO
1. What is the Amanta Healthcare IPO Date?
The IPO opens on September 1, 2025 and closes on September 3, 2025.
2. What is the Amanta Healthcare IPO Price Band?
The IPO price band is fixed at ₹120 – ₹126 per share.
3. What is the lot size for Amanta Healthcare IPO?
The lot size is 119 shares. Minimum investment is ₹14,994 for retail investors.
4. What is Amanta Healthcare IPO GMP today?
The current GMP is around ₹18 – ₹20 per share.
5. What are the main objects of Amanta Healthcare IPO?
The IPO proceeds will be used for expansion of new manufacturing lines and general corporate purposes.
6. Is Amanta Healthcare IPO good or bad for investment?
It may be good for short-term listing gains but comes with risks for long-term holding.
7. When will Amanta Healthcare IPO list on stock exchanges?
Tentative listing date is September 9, 2025 on NSE and BSE.
Disclaimer: This article is for educational and informational purposes only. It does not constitute investment advice or a recommendation to subscribe or avoid any IPO. Investors should carefully read the Red Herring Prospectus (RHP) and consult their financial advisor before making any investment decision.
- Amanta Healthcare IPO – Key Strengths, Risks and Long-Term Prospects Investors Should Know - August 28, 2025
- Amanta Healthcare IPO Review – Date, Price, GMP, Analysis – Should you Subscribe or Avoid? - August 28, 2025
- 10 Equity Mutual Funds Turn ₹ 10,000 SIP to Over ₹ 1 Crore in 15 Years - August 27, 2025
Discover more from Myinvestmentideas.com
Subscribe to get the latest posts sent to your email.